Major Tumor Shrinking and Persistent Molecular Remissions After Consolidation With Bortezomib, Thalidomide, and Dexamethasone in Patients With Autografted MyelomaMarco Ladetto, Antonio Palumbo, Vincenzo Callea et al.|Journal of Clinical Oncology|2010Cited by 268
Prospective, multicenter randomized GITMO/IIL trial comparing intensive (R-HDS) versus conventional (CHOP-R) chemoimmunotherapy in high-risk follicular lymphoma at diagnosis: the superior disease control of R-HDS does not translate into an overall survival advantageMarco Ladetto, Corrado Tarella, Federica De Marco et al.|Blood|2008Cited by 253
Long-term results of the GIMEMA VEL-03-096 trial in MM patients receiving VTD consolidation after ASCT: MRD kinetics' impact on survivalSimone Ferrero, Antonio Palumbo, Marco Ladetto et al.|Leukemia|2014Cited by 83
LONG-TERM RESULTS of the GIMEMA VTD Consolidation TRIAL In Autografted MULTIPLE Myeloma PATIENTS (VEL-03-096): IMPACT of Minimal RESIDUAL DISEASE Detection by REAL Time Quantitative PCR On LATE Recurrences and Overall SURVIVALMarco Ladetto, Antonio Palumbo, Simone Ferrero et al.|Blood|2011Cited by 9
Correlation Between Clinical Outcome and Disease Kinetics by Quantitative PCR in Myeloma Patients Following Post-Transplant Consolidation with Bortezomib, Thalidomide and Dexamethasone.Marco Ladetto, Antonio Palumbo, G Pagliano et al.|Blood|2009Cited by 6